<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>美药专利法观察 | wechat-feeds</title><link>http://MzU4MDkyNTYwNw.favicon.privacyhide.com/favicon.ico</link><description>介绍与医药相关的美国专利法规与诉讼案例</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 01 Feb 2021 12:03:42 +0800</pubDate><image><url>http://MzU4MDkyNTYwNw.favicon.privacyhide.com/favicon.ico</url><title>美药专利法观察 | wechat-feeds</title><link>http://MzU4MDkyNTYwNw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>美国上诉案例-专利保护的是创新的方法还是效果？</title><link>https://mp.weixin.qq.com/s/ApmD1orSPDz9-MK1L551Qg</link><description></description><content:encoded><![CDATA[美国上诉案例-专利保护的是创新的方法还是效果？]]></content:encoded><pubDate>Mon, 01 Feb 2021 07:44:04 +0800</pubDate></item><item><title>修美乐专利丛林违反反垄断法吗？鼓励创新和遏制垄断再引争议</title><link>https://mp.weixin.qq.com/s/iB6bPNEqy1ukBM3Yj-MPWg</link><description></description><content:encoded><![CDATA[修美乐专利丛林违反反垄断法吗？鼓励创新和遏制垄断再引争议]]></content:encoded><pubDate>Mon, 25 Jan 2021 07:03:05 +0800</pubDate></item><item><title>多肽药产品的名分之争，Teva遏制仿制药诉讼受挫</title><link>https://mp.weixin.qq.com/s/DSJd4a4-wFq5F2spYsLMoA</link><description></description><content:encoded><![CDATA[多肽药产品的名分之争，Teva遏制仿制药诉讼受挫]]></content:encoded><pubDate>Mon, 18 Jan 2021 06:33:39 +0800</pubDate></item><item><title>药片不设“目标”！本所团队完胜获专利无效上诉判决</title><link>https://mp.weixin.qq.com/s/znAGmJWnlYDrjc_EO2I7Bw</link><description></description><content:encoded><![CDATA[药片不设“目标”！本所团队完胜获专利无效上诉判决]]></content:encoded><pubDate>Mon, 11 Jan 2021 03:54:18 +0800</pubDate></item><item><title>美国上诉判决: 等同侵权-权利要求中化学名取代商品名未构成专利范围变窄</title><link>https://mp.weixin.qq.com/s/g6Z0OdN0Up6HJle5tulNlw</link><description></description><content:encoded><![CDATA[美国上诉判决: 等同侵权-权利要求中化学名取代商品名未构成专利范围变窄]]></content:encoded><pubDate>Mon, 04 Jan 2021 05:11:05 +0800</pubDate></item><item><title>2020年度美国重要相关专利案例回顾和进展</title><link>https://mp.weixin.qq.com/s/QoMdvV3tbT7DgLEX12mnsw</link><description></description><content:encoded><![CDATA[2020年度美国重要相关专利案例回顾和进展]]></content:encoded><pubDate>Mon, 28 Dec 2020 01:18:23 +0800</pubDate></item><item><title>美国上诉判决: 制剂专利的几个常见词是什么意思？</title><link>https://mp.weixin.qq.com/s/DuGrr1-B1RjKc3P0GV36pQ</link><description></description><content:encoded><![CDATA[美国上诉判决: 制剂专利的几个常见词是什么意思？]]></content:encoded><pubDate>Mon, 21 Dec 2020 05:22:24 +0800</pubDate></item><item><title>No Standing – 原告的诉讼“站得住脚”吗？</title><link>https://mp.weixin.qq.com/s/Wy5KPYOSBdRrJkm8THqjsA</link><description></description><content:encoded><![CDATA[No Standing – 原告的诉讼“站得住脚”吗？]]></content:encoded><pubDate>Mon, 14 Dec 2020 06:22:32 +0800</pubDate></item><item><title>美国专利无效上诉判决，及法律和事实两类问题的区别</title><link>https://mp.weixin.qq.com/s/zJz_XSK9mUzQ-8RVhgLBnA</link><description></description><content:encoded><![CDATA[美国专利无效上诉判决，及法律和事实两类问题的区别]]></content:encoded><pubDate>Mon, 07 Dec 2020 07:41:48 +0800</pubDate></item><item><title>美国上诉判决：注射剂仿制药侵权，老产品新专利的价值</title><link>https://mp.weixin.qq.com/s/qFUw8nt78VcfTb_r2c0R9g</link><description></description><content:encoded><![CDATA[美国上诉判决：注射剂仿制药侵权，老产品新专利的价值]]></content:encoded><pubDate>Mon, 30 Nov 2020 03:56:11 +0800</pubDate></item></channel></rss>